HopeStage
Back to all studies
CompletedNCT07545382

Rivastigmine as an Antidote for Clozapine-induced Central Nervous System Depression and Delirium

Medication studyAges 18+Egypt
The study in practice

Understand this study

Who was this study for?

Listed age limits: from 18 years.

Listed locations
AlexandriaSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: December 8, 2025
Recruitment status
Completed
Enrollment listed in the registry
100
Sponsor
Alexandria University
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
Egypt
Age range
Over 18 Years
Official registry ID
NCT07545382
Official title
Show the full official title

Efficacy of Rivastigmine in the Management of Toxic Anticholinergic Delirium: A Prospective Study at Alexandria Poison Center

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Alexandria

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Alexandria University, a university.

Did this study involve medication?

Yes. The study involved medication, including Rivastigmine.

Who was this study for?

Listed age limits: from 18 years.

Want to explore more studies?

Explore studies